rs8099917 — IFNL3

Intergenic variant upstream of IFNL3 — second major IL28B locus predictor of hepatitis C spontaneous clearance and treatment response, with independent predictive value over rs12979860 in Asian populations

See your personal result for IFNL3

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

IFNL3 Upstream — The Second Signal in Hepatitis C Immunity

Eight kilobases upstream of the interferon lambda-3 gene (IFNL3, formerly IL28B) on chromosome 19q13.13 sits a T/G polymorphism that has shaped how hepatitis C is treated across the world. The rs8099917 variant lies in the intergenic region between IFNL2 and IFNL3 and, like its more famous neighbour rs12979860, tags the same underlying interferon lambda locus haplotype11 interferon lambda locus haplotype
a cluster of variants in the IFNL2/3/4 region that collectively control innate antiviral immunity at hepatic and mucosal surfaces.

rs8099917 was actually the primary GWAS signal reported by Suppiah et al. in 200922 Suppiah et al. in 2009 — the study that first identified the IL28B region as the most powerful host genetic predictor of hepatitis C treatment response. In that landmark Australian study, the G allele was associated with an OR of 1.98 for sustained virologic response (SVR) failure. The rs12979860 variant only emerged as the more commonly cited marker after subsequent studies found it slightly more predictive in European populations, but for Asian patients rs8099917 has consistently proven to be the more informative marker.

The Mechanism

rs8099917 sits in an intergenic regulatory region and does not directly alter any protein sequence. Its effect is mediated through linkage disequilibrium33 linkage disequilibrium
non-random co-inheritance with nearby functional variants across the IFNL3/4 locus and with regulatory elements controlling IFNL3 (IFN-λ3) transcription.

The correlation between rs8099917 and rs12979860 varies substantially by ancestry — r²=0.43–0.65 depending on the population studied. This partial independence is clinically meaningful: among Japanese patients, rs8099917 captures predictive signal that rs12979860 misses.

The Evidence

The Suppiah et al. 2009 GWAS44 Suppiah et al. 2009 GWAS in 293 Australian patients (validated in 555 additional individuals) reported rs8099917 as the primary discovery signal for SVR to peginterferon/ribavirin, with combined OR 1.98 (95% CI 1.57–2.52, p=9.25×10⁻⁹). Simultaneously, Tanaka et al.55 Tanaka et al. identified rs8099917 among the strongest predictors of treatment response in Japanese HCV genotype 1 patients, with SVR rates declining sharply from TT to TG to GG carriers.

A meta-analysis of 36 studies comprising 10,912 patients66 meta-analysis of 36 studies comprising 10,912 patients quantified the TT genotype effect: in HCV genotype 1/4 patients receiving peginterferon/ribavirin, TT carriers achieved higher SVR versus non-TT with OR 2.54 (95% CI 2.11–3.07) in Caucasians and OR 5.21 (95% CI 3.69–7.36) in Asians.

For spontaneous clearance, a Japanese cross-sectional study77 Japanese cross-sectional study found TT genotype was independently associated with spontaneous HCV elimination with an adjusted OR of 9.39 in multivariate analysis including sex and age. A separate meta-analysis of spontaneous clearance studies88 meta-analysis of spontaneous clearance studies confirmed the association.

Overall SVR rates with modern pangenotypic DAA regimens exceed 95% regardless of IFNL3 genotype when standard 12-week durations are used.

Practical Actions

Carriers of one or two G alleles who have hepatitis C or are at risk should share their genotype with their hepatologist when planning treatment. For interferon-era therapy, the genotype was highly determinative.

Interactions

rs8099917 is in partial linkage disequilibrium with rs1297986099 rs12979860
the more commonly cited IL28B locus marker; r²=0.43–0.65 depending on population — partial independence means both SNPs provide additional information. Clinical HCV pharmacogenomics panels frequently report both rs8099917 and rs12979860 together because neither alone is sufficient across all ancestries — the combination provides near-complete haplotype information.

Drug Interactions

peginterferon alfa-2a reduced_efficacy literature
peginterferon alfa-2b reduced_efficacy literature
ribavirin reduced_efficacy literature
simeprevir reduced_efficacy literature

Genotype Interpretations

What each possible genotype means for this variant.

TT Favourable Genotype Beneficial

Favourable IFNL3 locus genotype — best innate antiviral immune response and HCV clearance

You have two copies of the T allele at rs8099917, which tags the favourable IFNL3/4 haplotype. This is associated with the strongest innate antiviral immune response at hepatic surfaces, the highest rates of spontaneous hepatitis C clearance, and the best response to interferon-based HCV therapy. About 55–65% of people of European or East Asian descent carry this genotype. If you were ever exposed to hepatitis C, your immune system was most likely to clear it without treatment.

GT One G Allele Intermediate

Intermediate HCV clearance — one unfavourable allele modestly impairs antiviral response

You carry one T allele and one G allele. This heterozygous genotype produces an intermediate innate antiviral immune phenotype at the IFNL3/4 locus. About 29–40% of people of European descent carry this genotype. Your spontaneous HCV clearance rate is intermediate between TT and GG carriers, and SVR rates with peginterferon-based treatment are modestly lower than TT. When you also have a rs12979860 CT result, your combined haplotype provides more complete risk information than either SNP alone.

GG Two G Alleles Reduced

Unfavourable IFNL3 locus genotype — significantly impaired HCV clearance and treatment response

The GG genotype at rs8099917 tags the same unfavourable IFNL3/4 haplotype as rs12979860 TT, though the two markers are only in partial linkage disequilibrium (r²=0.43–0.65 by population). This means some GG carriers will have a discordant rs12979860 result, and vice versa — your combined haplotype is more informative than either SNP alone. In the Japanese population, where the G allele is less common overall, GG homozygosity is a rare but strongly predictive genotype. Meta-analysis data show that in Asian patients with HCV genotype 1/4, the TT versus non-TT OR for SVR was 5.21 (95% CI 3.69–7.36). If you previously failed peginterferon/ribavirin therapy, this genotype explains much of that failure, and modern DAA regimens offer a realistic path to cure independent of IFNL3 genotype.